The C Diff Foundation, a 501(c) (3) non-profit organization, established in 2012, and comprised of 100% volunteering professionals dedicated at supporting public health through education and advocating for C. difficile infection (CDI) prevention, treatments, clinical trials, environmental safety worldwide.
There are many avenues connected to C. difficile infections which lead
the C Diff Foundation Members and Volunteer Patient Advocates down adjacent roads raising awareness of antibiotic-resistance, antibiotic stewardship programs, Sepsis, and a multitude of general wellness topics with fellow Government, Medical Provider, and Cause specific organizations; MD mag, Sepsis Alliance, CDC, Global Sepsis Alliance to name a few.
The Foundation’s founder is a Nurse and after suffering through C. difficile infections herself and witnessing the loss of her Father, whose life was claimed by C. difficile involvement, the
C Diff Foundation came to fruition. The C Diff Foundation Members, with their
Volunteer Patient Advocates, successfully “Raise C. diff. Awareness” nationwide and have touched lives in fifty-six countries. There is a U.S. Nationwide information Hot-Line (1-844-FOR-CDIF) to support health care providers, patients, and families to manage through the difficulties of a C. diff. infection. There are a variety of patient/family programs available to provide information and support.
An excerpt from USA Today article published in 2012: Deaths and illnesses are much higher than reports have shown. In March, the CDC said in a report that the C difficile infection kills 14,000 people a year. But that estimate is based on death certificates, which often don’t list the infection when patients die from complications, such as kidney failure. Hospital billing data collected by the federal Agency for Healthcare Research and Quality shows that more than 9% of C. diff-related hospitalizations end in death — nearly five times the rate for other hospital stays. That adds up to more than 30,000 fatalities among the 347,000 C. diff hospitalizations in 2010. Thousands more patients are treated in nursing homes, clinics and doctors’ offices.
“We’re talking in the range of close to 500,000 total cases a year,” says Cliff McDonald, a C. diff expert and senior science adviser in the CDC’s Division of Healthcare Quality Promotion. And annual fatalities “may well be … as high as 30,000.”
* AHRQ News and Numbers provides statistical highlights on the use and cost of health services and health insurance in the United States.
This is sound evidence and gives concrete reason why the C Diff Foundation continues with the Mission in Educating, and advocating for C difficile infection prevention, treatments, and environmental safety worldwide.
The continued global support of the C Diff Foundation’s mission is through collaborative efforts from healthcare providers, the general public, medical healthcare organizations, healthcare professionals, government agencies, villages to communities, which will result in positive results in the reduction of newly diagnosed Clostridium difficile cases and preventable deaths. In the USA: Nearly half a million Americans suffer from Clostridium difficile (C. diff.) infections in a single year according to a study released February 25, 2015 by the Centers for Disease Control and Prevention (CDC). **Approximately 29,000 patients died within 30 days of the initial diagnosis of C. difficile. Of those, about 15,000 deaths were estimated to be directly attributable to C. difficile infections (CDI), making C. difficile a very important cause of infectious disease death in the United States. More than 80 percent of the deaths associated with C. difficile occurred among Americans aged 65 years or older. C. difficile causes an inflammation of the colon and deadly diarrhea.
The Foundation’s mission is dedicated at reaching out to communities from villages to cities, to medical practitioners, medical students, C. diff. survivors, caregivers, and the patients combating a C. difficile infection (CDI) while providing the general public important information on prevention, treatments available, and EPA registered products available for environmental safety. We continue moving forward setting up outreach centers and building positive networks with the C Diff Foundation Volunteer Advocates aiding in “Raising C.diff. Awareness” worldwide.
If you have questions, and would like to register to join the C Diff Foundation Volunteer Advocate Program or wish to help us extend the outreach of the C Diff Foundation please contact us:
Office Hours: 900 a.m. to 5:00 p.m. EST, Monday-Friday
Office #: 1 – (727) – 205-3922
C Diff Foundation Board of Directors
Nancy C Caralla, Founding President, Executive Director,
Scott Battles, Vice President
Dr. Ahmed A. M. Al Mandalawi, MD, Medical Director
Tony DelMonaco, Secretary
Rowaland R. Dory, Vice Chair
Angelo Ortiz, Treasurer
C Diff Foundation Chair and Committees
Research and Development Committee
Dr. Simon Cutting, MS,PhD, Chairperson
Dr. Martha R. Clokie, MS, PhD
Dr. Norman Javitt, MD
Medical Advisory Board
Dr. Mark Wilcox, MD, Chairperson
Dr. Barbara McGovern, MD
C. diff. Global Community Support Program
Dr. Paul Feuerstadt, MD, Co-Director
Dr. Caterina Oneto, MD, Co-Director
Scott Battles – Support Leader
Karen Factor, RD- Support Leader
Roy Poole – Support Leader
C Diff Foundation Volunteer Health Advocate Program
Angelo Ortiz, Chairperson
Jennifer Boyle, VPA Admin. Assistant
Administrative Support Committee
Josh Factor, Fundraising/Grant Writing Development Coordinator
Scott Bauer, Administrative Support Intern
Jennifer Boyle, Office Admin. Support
Marketing and Graphic Arts Committee
Joel Davis, BS, Chairperson
Global Community Education & Outreach Programs
Paul Feuerstadt, MD, FACG, AGA-F – Director of Medical Education
Linda Jablonski, MS, BSN, RN-BC – Director Of Nursing
Linda Davis, BSN, RN-BC – Triage Coordinator
Nutrition and Wellness Committee
Karen Factor, RD, MS, Chairperson
Michele Martello, Wellness Advocate
Infectious Diseases Committee
Nicola Petrosillo, MD, Chairperson
Barley Chironda, RPN, CIC, Infection Prevention Advocate
Ron Romano, RN, Infection Prevention Advocate
Dr. Rosie Lyles, MD, Infection Prevention Advocate
Biologic Research and Development Committee
Michael Kaleko, MD, PhD, Senior Vice President, Reseaerch & Development Synthetic Biologics
Andy Bristol, PhD, Vice President, Research & Development, Synthetic Biologics
Main Office: 7813 Mitchell Blvd, Suite 106C, New Port Richey, FL 34655 USA
Phone: (727) – 205 – 3922
Fax: (727) – 205 – 3923